Pfizer asks FDA to OK Covid-19 booster shots for all adults
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Friday
August 19, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
FRIDAY, AUGUST 19, 2022
Pfizer asks FDA to OK Covid-19 booster shots for all adults

Coronavirus chronicle

UNB/AP
10 November, 2021, 09:05 am
Last modified: 10 November, 2021, 09:15 am

Related News

  • 212 Covid cases reported in 24 hours
  • Two Covid scares cause mayhem in Shanghai
  • Southern hemisphere to get first mRNA vaccine facility
  • North Korea lifts mask mandate, distancing rules after declaring Covid victory
  • Bangladesh logs 1 death, 214 Covid cases in 24 hours

Pfizer asks FDA to OK Covid-19 booster shots for all adults

Pfizer is submitting early results of a booster study in 10,000 people to make its case that it’s time to further expand the booster campaign

UNB/AP
10 November, 2021, 09:05 am
Last modified: 10 November, 2021, 09:15 am
Vials of the Pfizer-BioNTech Covid-19 vaccine sit in a cooler before being thawed at a pop-up Covid-19 vaccination site in the Bronx borough of New York on Tuesday, Jan. 26, 2021. On Tuesday, Nov. 9, 2021, Pfizer asked US regulators to allow boosters of its Covid-19 vaccine for anyone 18 or older, a step that comes amid concern about increased spread of the coronavirus with holiday travel and gatherings. Photo: UNB/AP
Vials of the Pfizer-BioNTech Covid-19 vaccine sit in a cooler before being thawed at a pop-up Covid-19 vaccination site in the Bronx borough of New York on Tuesday, Jan. 26, 2021. On Tuesday, Nov. 9, 2021, Pfizer asked US regulators to allow boosters of its Covid-19 vaccine for anyone 18 or older, a step that comes amid concern about increased spread of the coronavirus with holiday travel and gatherings. Photo: UNB/AP

Pfizer asked US regulators Tuesday to allow boosters of its Covid-19 vaccine for anyone 18 or older, a step that comes amid concern about increased spread of the coronavirus with holiday travel and gatherings.

Older Americans and other groups particularly vulnerable to the virus have had access to a third dose of the Pfizer and BioNTech vaccine since September. But the Food and Drug Administration has said it would move quickly to expand boosters to younger ages if warranted.

Pfizer is submitting early results of a booster study in 10,000 people to make its case that it's time to further expand the booster campaign.

While all three vaccines used in the US continue to offer strong protection against severe Covid-19 illness and death, the shots' effectiveness against milder infection can wane over time.

Pfizer's new study concluded a booster could restore protection against symptomatic infection to about 95%, even as the extra-contagious delta variant was surging. Side effects were similar to those seen with the company's first two shots.

A median of 11 months after their last Pfizer vaccination, trial participants were given either a third dose or a dummy shot. Researchers tracked any infections that occurred at least a week later, and so far have counted five cases of symptomatic Covid-19 among booster recipients compared to 109 cases among people who got dummy shots.

The Biden administration had originally envisioned boosters for all adults, but faced a stinging setback in September when the FDA's scientific advisers rejected extra Pfizer doses for everyone. The panel wasn't convinced that young healthy people needed another dose, particularly when most of the world's population remains unvaccinated, and instead recommended boosters just for certain groups — one of a series of decisions about extra doses for all of the three vaccines used in the US

The current rules: People who initially received Pfizer or Moderna vaccinations are eligible for a booster six months later if they're 65 or older, or are at high risk of Covid-19 because of health problems or their job or living conditions. Because the single-dose Johnson & Johnson vaccine hasn't proven as effective as its two-dose competitors, any J&J recipient can get a booster at least two months later.

Also, anyone eligible for a booster doesn't have to stick with their initial vaccination type and can get a different company's vaccine, what's called mixing and matching.

About 194 million Americans are fully vaccinated. Under today's policies, authorities already estimated about 2 of every 3 vaccinated adults could qualify for a booster within the next few months. Many who don't meet the criteria often score an extra shot because many vaccine providers don't check qualifications.

FDA spokeswoman Alison Hunt said the agency would review Pfizer's application "as expeditiously as possible," but would not set a timeline for a decision. She also said the FDA hasn't yet decided whether to convene its panel of outside experts to vet the data.

If the FDA authorizes Pfizer's request for expanded boosters, the Centers for Disease Control and Prevention then will make recommendations for how to use them.

Globally, boosters also are a hodge-podge. Some countries restrict them to older or medically fragile people while others have few restrictions. Israel, for example, has allowed Pfizer boosters for anyone 12 and older. Canada's health regulator on Tuesday authorized Pfizer boosters for people 18 and older.

Top News / World+Biz

Pfizer / FDA / Covid -19 / booster

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • The curious case of RMG import growth overtaking export’s
    The curious case of RMG import growth overtaking export’s
  • Photo: TBS
    Requested India to ensure PM Hasina's govt at any cost: Momen
  • Fuel price, rising costs push ride-sharers to the brink
    Fuel price, rising costs push ride-sharers to the brink

MOST VIEWED

  • N Korea's Kim praises military medics for frontline Covid fight in capital
    N Korea's Kim praises military medics for frontline Covid fight in capital
  • People walk at a subway station, following the outbreak of the coronavirus disease (Covid-19), in Shanghai, China May 11, 2021. REUTERS/Aly Song
    Two Covid scares cause mayhem in Shanghai
  • File Photo: A woman holds a small bottle labeled with a "Vaccine Covid-19" sticker and a medical syringe in this illustration taken April 10, 2020. Reuters/Dado Ruvic/Illustration
    Variant-adapted Covid vaccine wins first approval in Britain
  • Southern hemisphere to get first mRNA vaccine facility
    Southern hemisphere to get first mRNA vaccine facility
  • North Korea's leader Kim Jong Un greets health workers and scientists struggling with the coronavirus disease (Covid-19) pandemic during a photo session in Pyongyang, North Korea, in this undated photo released on August 10, 2022 by North Korea's Korean Central News Agency (KCNA). KCNA via REUTERS
    North Korea lifts mask mandate, distancing rules after declaring Covid victory
  • A motorist passes by a mural of frontline workers against coronavirus at RK Puram in New Delhi on July 25. Delhi’s Covid-19 recoveries have outstripped new cases on almost all days this month barring a few exceptions, after ramped-up containment and testing efforts over the past month or so. (Sanchit Khanna / HT Photo)
    Delhi to enforce mask mandate again after spurt in Covid cases

Related News

  • 212 Covid cases reported in 24 hours
  • Two Covid scares cause mayhem in Shanghai
  • Southern hemisphere to get first mRNA vaccine facility
  • North Korea lifts mask mandate, distancing rules after declaring Covid victory
  • Bangladesh logs 1 death, 214 Covid cases in 24 hours

Features

We will be facing massive, recurring challenges in the coming years no matter what. Photo: Reuters

Holes in the recession story

22h | Panorama
Illustration: Bloomberg

What nonmonogamy can teach moonlighters and job jugglers

21h | Pursuit
The members of BracU Dichari in Poland for the ERL Championship Round. Photo: Courtesy

BracU Dichari: A Bangladeshi robotics team on the world stage

23h | Pursuit
FundedNext aims to provide funds to traders with the best possible trading experience and to maximise the opportunity to unleash their true potential. Photo: Noor-A-Alam

FundedNext: A global prop-trading firm built by a Bangladeshi youth

23h | Panorama

More Videos from TBS

How economic journalism touches lives

How economic journalism touches lives

1h | Videos
City dwellers fed up with unbearable heat

City dwellers fed up with unbearable heat

1h | Videos
Love, marriage, trolls, and an unusual death

Love, marriage, trolls, and an unusual death

12h | Videos
Are elephants on the verge of extinction in Bangladesh?

Are elephants on the verge of extinction in Bangladesh?

13h | Videos

Most Read

1
From left Afzal Karim, Murshedul Kabir and Mohammad Jahangir
Banking

Sonali, Agrani and Rupali banks get new MDs

2
Russia now offers Bangladesh finished oil
Energy

Russia now offers Bangladesh finished oil

3
Photo: TBS
Bangladesh

5 crushed to death as BRT girder falls on car in Uttara

4
Photo: Collected
Economy

Bangladesh is not in a crisis situation: IMF

5
Dollar price drops by Tk8 in kerb market
Economy

Dollar price drops by Tk8 in kerb market

6
Eight more banks make unusual gains from forex dealings
Banking

Eight more banks make unusual gains from forex dealings

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net